Atle Fund Management AB Acquires Shares of 34,690 Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

Atle Fund Management AB purchased a new position in Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 34,690 shares of the company's stock, valued at approximately $2,202,000. Verona Pharma PLC American Depositary Share comprises about 1.0% of Atle Fund Management AB's portfolio, making the stock its 27th largest position.

Other large investors have also added to or reduced their stakes in the company. RTW Investments LP purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 4th quarter worth about $84,568,000. Wellington Management Group LLP lifted its position in shares of Verona Pharma PLC American Depositary Share by 61.0% in the 4th quarter. Wellington Management Group LLP now owns 3,025,241 shares of the company's stock worth $140,492,000 after purchasing an additional 1,146,609 shares during the period. Darwin Global Management Ltd. purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 4th quarter worth about $37,637,000. Point72 Asset Management L.P. purchased a new stake in shares of Verona Pharma PLC American Depositary Share in the 4th quarter worth about $33,019,000. Finally, Janus Henderson Group PLC lifted its position in shares of Verona Pharma PLC American Depositary Share by 59.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,667,165 shares of the company's stock worth $77,466,000 after purchasing an additional 624,370 shares during the period. Institutional investors own 85.88% of the company's stock.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In other Verona Pharma PLC American Depositary Share news, insider Kathleen A. Rickard sold 114,984 shares of Verona Pharma PLC American Depositary Share stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $8.82, for a total transaction of $1,014,158.88. Following the transaction, the insider owned 2,546,472 shares of the company's stock, valued at $22,459,883.04. The trade was a 4.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark W. Hahn sold 400,000 shares of Verona Pharma PLC American Depositary Share stock in a transaction that occurred on Wednesday, June 11th. The shares were sold at an average price of $11.40, for a total transaction of $4,560,000.00. Following the transaction, the chief financial officer directly owned 12,278,992 shares in the company, valued at $139,980,508.80. This represents a 3.15% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,965,800 shares of company stock valued at $20,056,881. 4.80% of the stock is owned by corporate insiders.

Verona Pharma PLC American Depositary Share Stock Up 0.1%

Verona Pharma PLC American Depositary Share stock traded up $0.11 during trading hours on Tuesday, hitting $105.01. The stock had a trading volume of 3,332,865 shares, compared to its average volume of 1,735,550. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $8.94 billion, a P/E ratio of -52.51 and a beta of 0.24. Verona Pharma PLC American Depositary Share has a 12-month low of $18.51 and a 12-month high of $105.30. The stock's 50-day moving average price is $87.55 and its 200-day moving average price is $70.00.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to the consensus estimate of $41.47 million. Equities research analysts anticipate that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on VRNA. Roth Capital cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 10th. TD Cowen cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. Truist Financial cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, July 9th. HC Wainwright reissued a "neutral" rating and set a $107.00 price target (up from $90.00) on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, July 14th. Finally, Canaccord Genuity Group cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and set a $107.00 price target for the company. in a research report on Wednesday, July 9th. Eleven research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, Verona Pharma PLC American Depositary Share presently has a consensus rating of "Hold" and a consensus target price of $109.00.

Verona Pharma PLC American Depositary Share Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.